Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2007

View Archived Issues

New therapeutic agents for cancer covered in recent patents

Novel vaccine may be useful to treat familial ALS

Merck Frosst and Nippon Soda patents disclose new agents for treating eye disorders

Recent patents claim novel therapeutic agents for inflammatory disorders

Lithium starts clinical evaluation for the treatment of spinal cord injury

AT-101 monotherapy induces responses in hormone-refractory prostate cancer

Addition of oblimersen to docetaxel may not be beneficial in advanced prostate cancer

Epix reviews 2006 accomplishments

Alpharadin improves survival in hormone-refractory prostate cancer

CCR5: a novel target for asthma therapy

Advancis discusses Amoxicillin PULSYS refusal to file letter with FDA

Migraine prophylaxis compound BF-1 completes first clinical trial

Fenretinide receives orphan drug designations in U.S. and E.U.

Xoma collaborations take new directions

Futura Medical announces DermaSys as brand name for gel technology

Evotec and Interprotein collaborate on IL-6 inhibitor program

TG-100801 completes first phase I study for macular degeneration

PPD acquires exclusive license to novel Ranbaxy statin

Davanat filed for E.U. orphan drug status, advancing in phase II trials

Jerini plans Q3 NDA submission for icatibant in HAE

Second part of phase I study investigates R-7128 in HCV genotype 1 patients

Enrollment completed in phase II trials of Uvidem in melanoma

Accentia acquires rights to Revimmune

Positive interim results for Albuferon in treatment-naive chronic HCV genotype 1

Preliminary progression-free survival data from phase III study of MyVax

Neumune increases survival in primates with acute radiation syndrome

Levemir approved in E.U. in combination with oral antidiabetic drugs

Prevenar recommended for E.U. approval for pneumonia and acute otitis media

Vaprisol approved for treatment of hypervolemic hyponatremia

Tykerb studied in phase III trial for head and neck cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...